when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
calendar
phase 2 initiation

phase 2_initiation

Shanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)

April 25, 2026HLX-43updated 5mo ago

community read0 votes

Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

Data sources

globaldata

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 2

phase 2 initiationHLX-35: Shanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)Apr 27, 2026
phase 1 initiationHLX-3901: Shanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)Apr 30, 2026

🐶 often sniffed alongside

top 3

tagBreast Cancer5 co-mentions · 1 sources
tagOncology4 co-mentions · 1 sources
companyShanghai Henlius Biotech Inc1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?